High risk of tuberculosis during infliximab therapy despite tuberculosis screening in inflammatory bowel disease patients in India

摘要

Background/AimsThe data on the risk of tuberculosis (TB) reactivation with infliximab (IFX) in patients with inflammatory bowel disease (IBD) from TB endemic countries, like India, is limited. The risk of TB reactivation on IFX and its predictors in patients with IBD was assessed.